Shares of RLI Corp. (NYSE:RLI) reached a new 52-week high and low during mid-day trading on Tuesday . The stock traded as low as $67.98 and last traded at $67.80, with a volume of 1829 shares changing hands. The stock had previously closed at $67.65.
RLI has been the topic of several recent research reports. Zacks Investment Research raised RLI from a “sell” rating to a “buy” rating and set a $72.00 price target on the stock in a research note on Tuesday, April 17th. ValuEngine raised RLI from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $59.33.
Top 5 Heal Care Stocks For 2019: Marten Transport, Ltd.(MRTN)
Advisors' Opinion:- [By Ethan Ryder]
New York State Common Retirement Fund grew its stake in shares of Marten Transport, Ltd (NASDAQ:MRTN) by 9.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,968 shares of the transportation company’s stock after acquiring an additional 10,000 shares during the period. New York State Common Retirement Fund’s holdings in Marten Transport were worth $2,690,000 at the end of the most recent quarter.
- [By Stephan Byrd]
Marten Transport (NASDAQ: MRTN) and YRC Worldwide (NASDAQ:YRCW) are both small-cap transportation companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
- [By Stephan Byrd]
Victory Capital Management Inc. lifted its stake in Marten Transport, Ltd (NASDAQ:MRTN) by 19.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,089 shares of the transportation company’s stock after buying an additional 3,410 shares during the quarter. Victory Capital Management Inc.’s holdings in Marten Transport were worth $481,000 at the end of the most recent reporting period.
- [By Max Byerly]
Schneider National (NYSE: SNDR) and Marten Transport (NASDAQ:MRTN) are both transportation companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.
- [By Stephan Byrd]
Strs Ohio lifted its holdings in shares of Marten Transport, Ltd (NASDAQ:MRTN) by 9.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,800 shares of the transportation company’s stock after acquiring an additional 3,200 shares during the quarter. Strs Ohio’s holdings in Marten Transport were worth $839,000 as of its most recent filing with the Securities and Exchange Commission.
Top 5 Heal Care Stocks For 2019: Washington Real Estate Investment Trust(WRE)
Advisors' Opinion:- [By Stephan Byrd]
Shares of Washington Real Estate Investment Trust (NYSE:WRE) have been assigned an average rating of “Hold” from the nine brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $31.33.
- [By Logan Wallace]
Get a free copy of the Zacks research report on Washington Real Estate Investment Trust (WRE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Washington Real Estate Investment Trust (NYSE:WRE) has received a consensus rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $29.75.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Washington Real Estate Investment Trust (WRE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 5 Heal Care Stocks For 2019: Cardiome Pharma Corporation(CRME)
Advisors' Opinion:- [By Logan Wallace]
Cardiome Pharma Co. (TSE:COM) (NASDAQ:CRME) – Stock analysts at Zacks Investment Research issued their Q2 2018 EPS estimates for Cardiome Pharma in a research note issued on Tuesday, May 22nd. Zacks Investment Research analyst J. Vandermosten anticipates that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter.
- [By Lisa Levin]
Cardiome Pharma Corp. (NASDAQ: CRME) is expected to post quarterly loss at $0.07 per share on revenue of $6.34 million.
Quest Resource Holding Corporation (NASDAQ: QRHC) is estimated to post quarterly loss at $0.09 per share on revenue of $24.85 million.
- [By Stephan Byrd]
Here are some of the media stories that may have impacted Accern’s rankings:
Get Cardiome Pharma alerts: Cardiome Pharma Corp (TSE:COM): Should The Recent Earnings Drop Worry You? (finance.yahoo.com) Pacira Pharmaceuticals Gets a Hold Rating from Canaccord Genuity (analystratings.com) As of May, 21 Analysts See $-0.20 EPS for Cardiome Pharma Corp. (CRME) (thecasualsmart.com) Cardiome Pharma Corp. (CRME) stock added 0.33% off its SMA-20 (thestocksnews.com) Cardiome Pharma (CRME) Upgraded to Sell at ValuEngine (americanbankingnews.com)Shares of CRME traded down $0.01 during mid-day trading on Wednesday, reaching $2.29. The company’s stock had a trading volume of 730 shares, compared to its average volume of 138,610. The firm has a market cap of $80.20 million, a price-to-earnings ratio of -2.53 and a beta of 0.19. The company has a debt-to-equity ratio of 2.47, a quick ratio of 3.99 and a current ratio of 4.80. Cardiome Pharma has a 52 week low of $2.28 and a 52 week high of $2.30.
Top 5 Heal Care Stocks For 2019: Terex Corporation(TEX)
Advisors' Opinion:- [By Max Byerly]
Terex (NYSE:TEX) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
- [By Lee Samaha]
Shares in construction equipment company Terex Corporation (NYSE:TEX) fell 12.2% in August, according to data from S&P Global Market Intelligence. Since most of the fall occurred in the immediate aftermath of the second-quarter earnings report, which came out on the last day of July, it's reasonable to conclude that investors didn't like something about Terex's presentation.
- [By Rich Smith]
Shares of Terex Corporation (NYSE:TEX) closed 10.1% lower on Wednesday, even as the construction equipment maker reported Q2 earnings that met or exceeded Wall Street's expectations.
- [By Logan Wallace]
Get a free copy of the Zacks research report on Terex (TEX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Asset Management One Co. Ltd. acquired a new stake in Terex Co. (NYSE:TEX) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 9,770 shares of the industrial products company’s stock, valued at approximately $365,000.
- [By Max Byerly]
Get a free copy of the Zacks research report on Terex (TEX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 5 Heal Care Stocks For 2019: Qiagen N.V.(QGEN)
Advisors' Opinion:- [By Logan Wallace]
Dynamic Technology Lab Private Ltd boosted its stake in Qiagen NV (NASDAQ:QGEN) by 100.5% in the first quarter, Holdings Channel reports. The firm owned 20,714 shares of the company’s stock after acquiring an additional 10,384 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Qiagen were worth $670,000 at the end of the most recent quarter.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Qiagen (QGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
Qiagen (NASDAQ:QGEN) last announced its quarterly earnings data on Tuesday, July 31st. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. The company had revenue of $377.20 million during the quarter, compared to analysts’ expectations of $376.89 million. equities analysts forecast that Qiagen NV will post 1.34 EPS for the current fiscal year.
- [By Joseph Griffin]
Qiagen (NYSE: QGEN) is one of 91 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Qiagen to related companies based on the strength of its valuation, profitability, risk, dividends, analyst recommendations, institutional ownership and earnings.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Qiagen (QGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment